Back to Dashboard$4.8B estimated savings over 10 years$2.1B estimated savings over 5 years$1.2B CBO-scored savings over 10 years$6.3B CBO-scored savings over 10 years$8.6B combined annual revenue of listed drugs
BioVenture Partners
OncologyPrecision MedicineBiopharma
28 provisions tracked
5 positive
15 negative
3 conflict
NegativeSec. CMS-2026-0089 · CMS Medicare Drug Price Negotiation
Medicare Part D Negotiation Methodology Update
OncoStar and KinaseX both eligible under expanded 9-year threshold. Combined revenue exposure of $2.3B — represents 74% of BioVenture annual revenue.
ACTION: Priority briefing with BioVenture CEO on revenue impact modeling. Coordinate with Van Hollen office on oncology carve-out language.
NegativeSec. CMS-2026-0142 · CMS Medicare Part B Payment Reform
Medicare Part B Drug Payment Rate Adjustment
CAR-T cell therapy reimbursement under Part B significantly affected. $373K per treatment — ASP+3% reduces hospital margin incentive to offer therapy.
ACTION: Commission economic analysis showing ASP+3% impact on CAR-T access. Brief Cornyn office on cancer treatment access implications.
NegativeSec. HR-4521 · Legislative — Biosimilar Competition
Biosimilar Competition Act
OncoStar faces biosimilar competition 18 months sooner under reformed patent dance. $1.4B revenue product with 3 biosimilar applicants in FDA pipeline.
ACTION: Defensive strategy — prepare BioVenture for accelerated lifecycle management. Brief Pallone on innovation investment impact.
NegativeSec. S-2847 · Legislative — Drug Pricing
Prescription Drug Affordability Act
KinaseX had 8.2% price increase in 2025 (CPI was 3.1%). Federal upper payment limit would require $156M in rebates retroactively.
ACTION: Model financial impact of retroactive rebate provisions. Prepare oncology access impact narrative for Hill engagement.
NegativeSec. CMS-2026-0178 · CMS IRA Drug Negotiation
IRA Drug Negotiation List Expansion (Round 3)
OncoStar ($1.4B) and KinaseX ($890M) both on Round 3 list. Combined 74% of BioVenture revenue subject to negotiation. CAR-T therapies not yet listed but likely Round 4.
ACTION: Priority CEO briefing. Model negotiation scenarios at 40%, 50%, and 60% price reduction. Prepare oncology access impact narrative.